Cipla maintains its US revenue projection of $1 billion, despite supply issues

What happened

Cipla still expects to reach $1 billion in yearly US revenue by year-end, driven by its existing pipeline. Its net profit for the quarter ended September 30, 2026, fell 35 per cent to ₹878 crore, while revenue fell to ₹7,404 crore.

Confirmed

Global impact / market context

The US is a key growth market for Cipla, so hitting the $1 billion target would offset weaker quarterly results. Profit fell sharply because lanreotide supply problems in the US and geopolitical issues hurt sales, which means investors face uncertain near-term earnings.

Analyst inference

Cipla's US business brought in $172 million this quarter, a small share of the $1 billion goal, so most of the target depends on new products like respiratory drugs and a peptide. Supply fixes and a second manufacturing source are central to that plan.

Analyst inference

What to watch

1. Cipla is working with Pharmathen International, the maker of lanreotide, to fix its issues with the US Food and Drug Administration, which regulates medicines. Confirmed
2. Cipla says it found a second source for lanreotide to reduce the impact of the supply problems; watch whether that source starts supplying. Confirmed
3. Watch whether respiratory products and the peptide lift US revenue toward $1 billion by year-end, since $172 million this quarter leaves a large gap to close. Analyst inference

Evidence

• Original source link unavailable